# How to Size the TAM for a Healthcare or Medtech Company: A Step-by-Step Investor Guide > Accurately sizing the total addressable market for a healthcare or medtech company requires layering epidemiological data, reimbursement reality, and competitive displacement math rather than recycling analyst headline numbers. This guide walks through every step, the primary sources to check, and the most common mistakes that inflate TAM claims. ## Why Most Healthcare TAM Estimates Are Wrong Before You Even Start The single most common mistake in healthcare market sizing is confusing the theoretical disease burden with the commercially addressable opportunity. A company targeting Type 2 diabetes does not have a TAM equal to every adult with the condition worldwide. The real TAM is constrained by reimbursement coverage, prescriber access, care-setting eligibility, and competitive displacement probability. Start by rejecting any TAM figure that is not built from the bottom up. ## What Are the Three Core Methods for Sizing Healthcare TAM? Three methods work in practice, and the strongest analyses use all three as a cross-check. **Top-down sizing** starts with a published market report (IQVIA, GlobalData, Grand View Research, Mordor Intelligence) and carves out the relevant segment. This is fast but notoriously unreliable. Analyst firms frequently aggregate indications, geographies, or care settings that the company cannot actually reach. Use these numbers as a sanity check only, never as the primary source. **Bottom-up sizing** is the gold standard. The formula is: Target Patient Population multiplied by Annual Revenue Per Patient. Each input must be sourced and justified separately. **Value-based sizing** estimates the economic value displaced in the current care pathway. This is essential for novel devices, diagnostics, and digital health tools where no direct comparator market exists yet. ## How Do You Find the True Target Patient Population? Start with epidemiology, not market reports. The primary sources are: - **CDC National Center for Health Statistics** (wonder.cdc.gov) for U.S. prevalence and incidence - **PubMed** (pubmed.ncbi.nlm.nih.gov) for peer-reviewed natural history studies that define the specific subpopulation meeting the company's indication criteria - **ClinicalTrials.gov** for enrollment criteria in pivotal trials, which define who will actually be eligible post-approval - **CMS Medicare and Medicaid claims data** (data.cms.gov) for diagnosed, treated, and billed patient counts by ICD-10 code The key discipline is to apply sequential filters. Start with total diagnosed prevalence, then reduce for the subpopulation meeting the clinical label, then reduce again for the subset that is treatment-eligible, then reduce for patients in covered care settings. Each reduction should cite a specific source. ## How Do You Build the Revenue Per Patient Input? This is where most investor models get sloppy. Revenue per patient is not the list price. It is the net realized revenue after payer contracting, patient assistance programs, and site-of-care adjustments. For reimbursement data, check: - **CMS fee schedules** (cms.gov) for Medicare Part B and D pricing - **DRG lookup tools** for inpatient device reimbursement rates - **FDA 510(k) and PMA databases** (accessdata.fda.gov) to confirm the regulatory pathway because it determines reimbursement eligibility timelines - **AMA CPT code lookup** to verify whether a billing code exists; if it does not, assume a two-to-four year delay before widespread reimbursement For diagnostics and devices, confirm whether a Category I CPT code is in place. A technology with only a Category III (tracking) code or no code at all faces severe near-term commercial constraints that should shrink your near-term TAM materially. ## What Role Does Competitive Displacement Play in TAM? TAM represents the full market assuming 100 percent penetration, but you must separately build a Serviceable Addressable Market (SAM) and Serviceable Obtainable Market (SOM). For TAM sizing specifically, competitive displacement math helps validate ceiling assumptions. If the clinical evidence from PubMed and ClinicalTrials.gov shows that the new therapy replaces an existing drug class, the TAM should be benchmarked against the revenue of that drug class in CMS data and IQVIA channel data, not the theoretical disease burden. Also check **SEC EDGAR** (sec.gov/edgar) for 10-K filings from public competitors. Their disclosed revenue, net price per unit, and patient count disclosures are primary-source anchors for your per-patient revenue assumption. ## How Do You Validate or Challenge a TAM Claim in a Pitch Deck? When a company presents you with a TAM figure, ask for these five things in writing: 1. The primary epidemiology source with publication year and geography 2. The ICD-10 code or codes used in any claims data pull 3. The CPT or HCPCS billing code and its reimbursement status 4. The net price assumption and the source (CMS fee schedule, a comp company's 10-K, or management estimate) 5. The list of filters applied to reduce gross prevalence to the treated, covered, eligible subpopulation If any of these five are missing, the TAM is a placeholder, not an analysis. ## What Are the Most Common TAM Mistakes in Medtech and Healthcare? - Citing global addressable market when the company has U.S.-only regulatory clearance - Using list price instead of net realized revenue per patient - Ignoring the reimbursement lag between FDA clearance and widespread payer coverage - Counting patients who lack access to a specialist or facility that can deliver the therapy - Treating a pipeline indication as equivalent to an approved indication in terms of patient volume - Pulling a single analyst report number without checking the methodology appendix ## TAM Sizing Checklist for Healthcare Investors - Source prevalence from CDC, PubMed, or CMS claims data, not just analyst reports - Apply sequential eligibility filters using trial enrollment criteria from ClinicalTrials.gov - Confirm FDA clearance status and indication scope on accessdata.fda.gov - Verify CPT or HCPCS code category and reimbursement rate on cms.gov - Anchor net revenue per patient to a public comp's 10-K on SEC EDGAR - Cross-check bottom-up result against top-down analyst estimate as a sanity range - Separately state geographic scope and adjust for ex-U.S. regulatory and reimbursement timelines - Document every assumption with a clickable primary source ## How MedFuel Intel Automates This for Healthcare Investors Building a rigorous TAM model from primary sources takes eight to twelve hours of manual database work per company. MedFuel Intel automates the most time-consuming steps by pulling live data from FDA databases, CMS fee schedules, ClinicalTrials.gov, SEC EDGAR, and PubMed, then flagging inflated TAM claims, missing reimbursement codes, and unsourced prevalence figures in a structured AI due-diligence report with primary-source citations attached. Run a free Red Flag Screener on any healthcare or medtech company at [medfuelintel.com](https://medfuelintel.com) and get an instant summary of whether the TAM claim holds up against the underlying primary sources. --- Informational only, not investment advice. --- Source: MedFuel Intel (https://www.medfuelintel.com/geo/article/how-to-size-the-market-tam-for-a-healthcare-or-medtech-company). Grounded in primary-source-verified events; verify against SEC, FDA, and ClinicalTrials.gov before any investment decision.